Skip to Content


In the US, Eribulin (eribulin systemic) is a member of the drug class mitotic inhibitors and is used to treat Breast Cancer, Breast Cancer - Metastatic and Liposarcoma.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Cytostatic agent

Microtubule inhibitor


Chemical Name

(2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-2-[(2S)-3-amino-2-hydroxypropyl]-3-metoxy-26-metyl-20,27-dimetylidenehexacosahydro-11,15:18,21:24,28-triepoxy-7,9-etano-12,15-metano-9H,15H-furo[3,2-i]furo[2',3':5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one (WHO)

Foreign Names

  • Eribulinum (Latin)
  • Eribulin (German)
  • √Čribulin (French)
  • Eribulina (Spanish)

Generic Names

Brand Names

  • Halaven
    Eisai, Greece; Eisai, Hong Kong; Eisai, Lithuania; Eisai, Poland; Eisai, Romania; Eisai, Serbia; Eisai, Slovenia; Eisai, Slovakia; Eisai Europe, Cyprus; Eisai Laboratórios, Brazil; Eisai, Australia; Eisai, Canada; Eisai, Czech Republic; Eisai, Germany; Eisai, Denmark; Eisai, Finland; Eisai, France; Eisai, United Kingdom; Eisai, Ireland; Eisai, Israel; Eisai, Iceland; Eisai, Japan; Eisai, South Korea; Eisai, Malaysia; Eisai, Norway; Eisai, Philippines; Eisai, Sweden; Eisai, Thailand; Eisai, United States; Eisai Europ Limited, Bosnia & Herzegowina; Eisai Farmaceutica, Spain; Eisai NV, Belgium; PharmaSwiss, Estonia; PharmaSwiss, Croatia (Hrvatska); Eisai Singapore, Singapore
  • Halaven 0.44 mg/ml
    Eisai, Austria; Eisai, Hungary; Eisai Ltd, Luxembourg; Haemato Pharm, Austria; Orifarm, Austria
  • Halaven 1mg/2ml
    Eisai Pharma, Switzerland


BANBritish Approved Name
BANMBritish Approved Name (Modified)
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.